Nanomedical Diagnostics Launches New Getting Started Kit for Agile R100 Label-free Personal Assay System

Share Article

The GSK enables a new user to learn how to characterize small molecules using the breakthrough kinetic binding platform in under four hours.

Agile R100 graphene biosensor Getting Started Kit

Using the Getting Started Kit with Agile R100

“The GSK has removed the mystery of kinetic characterization for any researcher who wants to use information-rich data to make better decisions earlier in the drug discovery process.

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new Getting Started Kit (GSK), a self-training package for Agile R100 and Field Effect Biosensing (FEB) technology. Designed to be completed by a new user in four hours at a personal benchtop, the GSK comes with materials and reagents to run a positive binding interaction on the label-free Agile R100 assay platform. It guides a new user through FEB fundamentals, protocol design, use of the system, and understanding the data analysis provided by Agile Plus software.

“The GSK was an invaluable tool for introducing me to the Agile R100 platform,” says Dr. Marsha Kowal, Scientist at Base Pair Biotechnologies, a customer of Nanomedical Diagnostics. “In a few hours, I was able to complete an entire experiment successfully, from protocol design all the way through data analysis. After finishing the GSK, I was immediately ready to start running my own experiments.”

Previous label-free kinetic binding platforms are complicated systems that can require multi-day training courses, but Agile R100’s single-sample, easy-to-learn format makes the self-training GSK possible. Sample is pipetted directly onto the biosensor surface, and intuitive Agile Plus software presents real-time results instantaneously. “Until now, you needed a specialist with days of training and potentially years of experience to gain and analyze kinetic binding data,” says Ross Bundy, CEO of Nanomedical Diagnostics. “The GSK combined with Agile R100 which has no complicated processes or mechanics to learn, has removed the mystery of kinetic characterization for any researcher who wants to use information-rich data to make better decisions earlier in the drug discovery process.”

Agile R100 is the first and only kinetic characterization system built with proprietary Field Effect Biosensing (FEB) technology, a breakthrough electrical technique for measuring biomolecular interactions in real time. The system’s single-sample format lets researchers apply sample directly to the sensor surface, making it easy to characterize drug interactions.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay provide highly-sensitive kinetic characterization of small molecules and proteins in complex solutions from solvents and detergents to cell fractions and tissue lysate. Using just a 10 µL drop of sample, the platform is a cutting-edge orthogonal technique for drug discovery hit validation.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website